Quality of life and neurocognitive function are important clinical outcome measures for patients with lower grade glioma. In this pilot study, we performed neurocognitive testing and quality of life assessments in radiologically and clinically stable grade II and III glioma patients who were not receiving active treatment. We found novel associations between standard clinical assessments and neuroimaging metrics at pre-surgical and follow-up timepoints. Further characterizing the longitudinal relationship between structural and functional neuroimaging, neurocognition and quality of life will better allow clinicians to proactively intervene to help patients in future.
This abstract and the presentation materials are available to members only; a login is required.